ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China
ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV) and LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced an exclusive collaboration and license agreement for the development and commercialization of sisunatovir in mainland China, Hong Kong, Macau, and Singapore. Sisunatovir is ReViral’s lead small molecule for the treatment of RSV, currently in Phase 2 clinical studies in pediatric and adult immunocompromised patient populations.
Under the terms of the collaboration, ReViral will receive an upfront cash payment of $14 million and is eligible to receive development and commercial milestone payments of up to $105 million. In addition, ReViral is eligible to receive tiered low double-digit royalties on sisunatovir net sales in the licensed territories. LianBio will be responsible for the development and commercialization of sisunatovir in the licensed territories, and ReViral will continue to be responsible for the development and commercialization of sisunatovir in all other geographies.
“We are delighted to be entering into this collaboration with LianBio to advance sisunatovir in China, a market with a significant unmet medical need for patients with serious RSV infection,” said Alex Sapir, CEO, ReViral. “LianBio shares our vision of developing and commercializing world-class therapies, and we look forward to leveraging their deep clinical and regulatory expertise in China to bring sisunatovir to this important market.”
“In China alone, more than 3.3 million pediatric and elderly patients develop RSV-associated lower respiratory tract infections each year, including an estimated 400,000 patients who require hospitalization,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman, LianBio. “The compelling clinical data ReViral has generated to date suggest sisunatovir has the potential to be a highly effective treatment option for RSV. We look forward to partnering with ReViral to bring sisunatovir to Chinese patients as